Conference Coverage

Sotagliflozin’s HFpEF benefit confirmed by new analyses



It’s now official: The investigational sodium-glucose cotransporter (SGLT) 1/2 inhibitor sotagliflozin is the first agent clearly shown in a prespecified analysis of randomized trials to improve clinical outcomes in patients with heart failure with reduced ejection fraction (HFpEF).

Dr. Deepak L. Bhatt, professor of medicine, Harvard Medical School, Boston

Dr. Deepak L. Bhatt

Researchers who ran the SCORED and SOLOIST-WHF pivotal trials for sotagliflozin first made that claim in November 2020 when reporting top-line results from a prespecified meta-analysis of the two trials during the American Heart Association annual scientific sessions. A follow-up report during the annual scientific sessions of the American College of Cardiology fleshed out the evidence and firmed up their landmark conclusion.

The meta-analysis (Abstract 410-08) included 4,500 patients with type 2 diabetes and diagnosed heart failure at entry; its primary endpoint, which was the same in both trials, was the combined incidence of cardiovascular death and the total number of either hospitalization for heart failure or urgent outpatient visits for heart failure.

Compared with placebo, treatment with sotagliflozin for a median of about 15 months dropped this composite endpoint by a relative 33% among the 1,931 who began the study with a left ventricular ejection fraction (LVEF) of at least 50% (HFpEF), by a relative 22% in the 1,758 patients who entered with an LVEF of less than 40% (patients with heart failure with reduced ejection fraction), and by a relative 43% among the 811 patients who began with an LVEF of 40%-49% (patients with heart failure with mid-range ejection fraction). The relative risk reductions were significant for all three subgroups, Deepak L. Bhatt, MD, reported at the meeting.

Equally effective ‘across the full range of LVEFs.’

Perhaps as notable and unprecedented was the further finding that the clinical benefits seen with treatment of patients with type 2 diabetes with sotagliflozin was consistent regardless of the ejection fraction they had at entry. Enrolled patients with baseline LVEFs in the range of 25% received a relative benefit from sotagliflozin treatment that was statistically no different from the benefit seen in patients who entered with an LVEF in the neighborhood of 45%, 65%, or at any other level across the LVEF spectrum, a finding that Dr. Bhatt called “remarkable” during a press briefing. “The results show the benefit of sotagliflozin across the full range of LVEFs.”

“We are very excited in the heart failure world by the SGLT2 inhibitors; we’ve been impressed by their reduction in heart failure hospitalizations, but we wonder about the patients with HFpEF, where we haven’t had a blockbuster drug to give,” said Ileana L. Piña, MD, a heart failure specialist and medical officer with the Food and Drug Administration.

The new findings “look like they could pose a regulatory indication [for sotagliflozin] for patients with type 2 diabetes and heart failure across the entire spectrum of heart failure,” said Christopher M. O’Connor, MD, a heart failure specialist and president of the Inova Heart & Vascular institute in Falls Church, Va., and designated discussant for Dr. Bhatt’s report.

Dr. Christopher M. O'Connor, a heart failure specialist and president of the Inova Heart and Vascular Institute in Fairfax, Va.

Dr. Christopher M. O'Connor

SCORED randomized 10,584 patients with type 2 diabetes and chronic kidney disease to treatment with sotagliflozin or placebo on top of guideline-directed medical therapy. During a median 16 months of treatment, the combined primary endpoint occurred at a rate of 5.6 events/100 patient years on sotagliflozin and 7.5 events/100 patient years in the controls, a significant 26% relative reduction with sotagliflozin (N Engl J Med. 2021 Jan 14;384[2]:129-39). Nearly a third of the enrolled patients had heart failure, with representation across the range of LVEF.

SOLOIST-WHF randomized 1,222 patients with type 2 diabetes who were recently hospitalized for worsening heart failure. During a median 9 months of follow-up, the primary endpoint occurred at a rate of 51 events/100 patient years in the sotagliflozin-treated patients and a rate of 76 events/100 patient years in the controls, a significant 33% relative reduction with sotagliflozin (N Engl J Med. 2021 Jan 14;384[2]:117-28). Both trials stopped prematurely because of sponsorship issues.

In addition to the 4,500 patients with heart failure at entry in both trials, SCORED included a total of more than 6,700 without diagnosed heart failure at baseline, and in this subgroup treatment with sotagliflozin cut the incidence of the primary endpoint by a significant 27% compared with control patients.


Recommended Reading

FDA blazes path for ‘real-world’ evidence as proof of efficacy
MDedge Cardiology
ACC 21 looks to repeat success despite pandemic headwinds
MDedge Cardiology
BERENICE: Further evidence of heart safety of dual HER2 blockade
MDedge Cardiology
PARADISE-MI: Sacubitril/valsartan can’t beat ramipril in patients with acute MI
MDedge Cardiology
LAAOS III: Surgical LAA closure cuts AFib stroke risk by one third
MDedge Cardiology
Nasal spray resurrected after showing clinical benefits for PSVT
MDedge Cardiology
Novel rehab program fights frailty, boosts capacity in advanced HF
MDedge Cardiology
Dapagliflozin misses as treatment for COVID-19 but leaves intriguing signal for benefit
MDedge Cardiology
FIDELIO-DKD: Finerenone cuts new-onset AFib in patients with type 2 diabetes and CKD
MDedge Cardiology
Underlying heart rhythm, not ICD shocks, drives mortality
MDedge Cardiology